

Transportation ☐ Communications ☐ International Union

Los Angeles County Metropolitan Transportation Authority Health &
Welfare Trust Fund

Administered By: Benefit Programs Administration Telephone ☐

(562) 463-5090 ☐ (800) 427-5342

www.tcu-mtawelfare.org

July 2025

To: Eligible Participants (Including Spouses) Enrolled in the Transportation Communications
International Union – Los Angeles County Metropolitan Transportation Authority Health
& Welfare Trust Fund
From: The Board of Trustees
Re: Galleri Cancer Screening Test

Dear Eligible Participant,

This notice is to advise you of a new benefit offering made available to you by the Board of Trustees of The Transportation Communications International Union – Los Angeles County Metropolitan Transportation Authority Health & Welfare Trust Fund.

Effective **July 1, 2025**, you will be able to take the Galleri Cancer Screening Test in order to proactively screen for more than 50 types of cancer at no cost to you. Please note that only participants (including spouses) enrolled in the Transportation Communications International Union – Los Angeles County Metropolitan Transportation Authority Health & Welfare Trust Fund that are over the age of 50 or those who are 40-49 with qualifying risk factors are eligible to take this test.

Galleri is a multi-cancer early detection (MCED) blood test that can be done annually, screening for many aggressive cancers before symptoms appear.^{1,2,3} In a clinical study, the Galleri test was able to detect a signal shared by more than 50 types of cancer.³

Ordering your Galleri test is simple! Head to www.galleri.com/tcu-mtawelfare and request your test. When requesting the Galleri test you will need to provide an Access ID to confirm eligibility for the benefit. Your Access ID is your badge number.

You can also access the www.galleri.com/tcu-mtawelfare website by scanning the QR code below:



Please refer to the FAQs on the following pages for additional information about the Galleri test.

Please keep this important notice with your Summary Plan Description (SPD) for easy reference to all Plan provisions. Should you have any questions, please contact the Administration Office at (562) 463-5090 or (800) 427-5342.

Receipt of this notice does not constitute a determination of your eligibility. If you wish to verify eligibility, or if you have any questions regarding the Plan changes, please contact the Fund Office.

Galleri Test FAQs

For Eligible Participants Enrolled in the Transportation Communications International Union – Los Angeles County Metropolitan Transportation Authority Health & Welfare Trust Fund

1. Who is eligible for the Galleri test?

Participants (including spouses) enrolled in the Transportation Communications International Union – Los Angeles County Metropolitan Transportation Authority Health & Welfare Trust Fund that are over 50 years of age or those 40-49 years old with certain risk factors. Pregnant participants or those undergoing cancer treatment are not eligible.

2. Why is there an age restriction for taking the Galleri test?

Age is the biggest risk factor for cancer. Adults over age 50 are 13 times more likely to have cancer compared to people under the age of 50.⁴ Cancer risk increases for everyone as they age, regardless of family history.⁴

3. What are the risk factors for those age 40-49 that would make me eligible?

To review the full eligibility criteria, including the most updated risk factors, please visit www.galleri.com/tcu-mtawelfare.

The following are the current risk factors. However, please note that they are subject to change. The www.galleri.com/tcu-mtawelfare will have the most up to date information.

Individuals who are 40-49 years old are eligible to take Galleri as part of this program if they meet the criteria outlined below:

- 40-49 years old AND at least one of the following risk factors:
 - Cancer survivor who has completed treatment at least 5 years ago*
 - Currently smokes or quit smoking less than 10 years ago
 - Diagnosis of cirrhosis or chronic Hepatitis B or C infection
 - Infection with certain strains of HPV (e.g. HPV 16 or 18)
 - Known hereditary cancer syndrome
 - Confirmation or documentation of a gene mutation associated with increased cancer risk (e.g., Li-Fraumeni syndrome, Hereditary Breast and Ovarian Cancer syndrome [BRCA1/2], Lynch syndrome, and CHEK2).

OR

- 40-49 years old AND at least two of the following risk factors:
 - Documented genetic predisposition (germline variant)
 - First degree relative with cancer**
 - History of HIV infection
 - Current use of immunosuppressive therapies after solid organ transplant
 - Diabetes
 - BMI:

1200 Wilshire Blvd., Fifth Floor, Los Angeles, CA 90017-1906

- Female ≥ 30 kg/m²
- Male ≥ 35 kg/m²

* excludes basal or squamous cell carcinoma of the skin

** excludes basal or squamous cell carcinoma of the skin and/or the second cancer is not a recurrence or metastasis

4. How can I order the Galleri test?

To access the Galleri test as a covered benefit, you must request the test through www.galleri.com/tcu-mtawelfare. When requesting through this website, an independent healthcare provider from Recuro Health will review your request and order the test if appropriate. The test is prescription only.

5. Who is Recuro Health?

Recuro Health is an independent telemedicine, nationwide care provider and a GRAIL partner, supporting virtual physician consultations related to receiving the Galleri test. A Recuro Health physician will review your test request and order the test, if appropriate. A Recuro Health provider will also share your test result with you.

6. How much does the Galleri test cost?

The cost of the Galleri test, blood draw, and laboratory fees are all covered under this benefit at no cost to eligible participants (including spouses).

An at-home or in-lab blood draw is included in the price of the test if scheduled with a Galleri partner lab. Find a time and location convenient for you at Galleri.com/schedule.

7. What is my Access ID?

When requesting the Galleri test you will need to provide an "Access ID" to confirm eligibility for the benefit. Your "Access ID" is your or your spouse's badge number.

8. When should I take the Galleri test again if I receive a "No Cancer Signal Detected" result?

You will be able to complete the Galleri test every year.

9. Can I order the test through my primary care physician?

To access the Galleri test as a covered benefit, you must request the test through www.galleri.com/tcu-mtawelfare. An independent physician from Recuro Health will review your request and order the test, if appropriate.

10. Where can I go to learn more about Galleri?

For more information, visit www.galleri.com/tcu-mtawelfare.

About the Galleri Test

11. What is the Galleri test?

Galleri is a multi-cancer early detection test that can be taken as a simple annual blood test and screens for many of the deadliest cancers before they become symptomatic.

12. Who is GRAIL?

GRAIL is a healthcare company focused on improving health by pioneering new technologies for early cancer detection. GRAIL is the company that manufactures the Galleri multi-cancer early detection test. You may receive information or communications from GRAIL about your benefit or the Galleri test.

13. How does the Galleri test look for cancer?

Cancers growing in the body shed DNA into the bloodstream.^{3,5,6} Although there are many types of cancer, the DNA fragments can act like a unique "fingerprint" of cancer. This Galleri test screens for many of the deadliest cancers before they become symptomatic, including those without recommended screening tests.^{1,3} When there is a Cancer Signal Detected, the results also provide predicted Cancer Signal Origin* to help your healthcare provider determine the next steps for diagnosis.

14. I am not at risk for cancer nor do I have a family history, is the Galleri test really for me?

More than 1 in 3 people will develop cancer in their lifetime.⁷ People over the age of 50 have a 13 times higher risk for cancer than those under 50. Cancer risk increases for everyone as they age, regardless of family history⁹ — only 5% to 10% of cancers are inherited.^{4,8}

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. Talk to your provider about your risk for cancer, and whether the Galleri test is right for you.

Learn more about cancer risk

15. What cancer does the Galleri test detect?

In a clinical study, Galleri detected a signal shared by over 50 types of cancer - including some fast-spreading and aggressive cancers responsible for approximately two-thirds of cancer deaths.³ Galleri is a cancer screening test, meaning it looks for cancer before symptoms appear. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood.

Please visit <https://www.galleri.com/what-is-galleri/types-of-cancer-detected> to see the list of cancers screen by the Galleri test. Please note that false positive and false negative results do occur.

16. How accurate is the Galleri test?

Nearly 99% of people who take the Galleri test will receive a No Cancer Signal Detected result. A Cancer Signal Detected result is expected in approximately 1% of Galleri tests in people over 50 years of age. After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis.⁹

Some of the ways Galleri measures test accuracy is with positive predictive value (PPV) and a false positive rate. A PPV is the probability that a person with a Cancer Signal Detected test result has cancer. In a recent study the PPV was 43.1% for study participants with a Cancer Signal Detected result who were diagnosed with cancer. The false positive rate was 0.5% for participants without cancer.⁹

17. Is Galleri a genetic risk assessment test that predicts your future risk for cancer?

No, a genetic or hereditary risk assessment is a one time only measurement and assesses your future risk of developing cancer. The Galleri test is a point-in-time test that identifies DNA in the bloodstream shed by cancer cells and screens for cancer at the time of testing.

Galleri Test Logistics

18. How do I complete my blood draw?

If your test request is approved by Recuro Health, you will be shipped a Galleri test kit. You will also be provided with instructions on how to schedule your blood draw for a time and place convenient for you. Visit: [Galleri.com/schedule](https://www.galleri.com/schedule) to select either

- A partner lab
- A mobile phlebotomy option
 - A trained technician will come to your home, office, or any preferred location to complete your blood draw

Lab options vary by zip code. If you need assistance scheduling your blood draw appointment, please contact GRAIL's Customer Service team by email at customerservice@grail.com or by telephone at (833) 694-2553.

19. What happens to my blood sample when it is received at the GRAIL lab?

Learn more about how your sample is processed at the GRAIL laboratory by [watching this video](#).

1200 Wilshire Blvd., Fifth Floor, Los Angeles, CA 90017-1906

20. I was shipped a Galleri collection kit. How do I handle the collection kit once I receive it?

Once you receive your sample collection kit, please do not break the quality seal on it. The collection kit should be opened by the trained technician who draws your blood sample.

Store the kit at room temperature until your blood draw appointment. The contents are sensitive to extreme temperatures. For example, do not store the collection kit in a car.

To schedule your blood draw visit: [Galleri.com/schedule](https://www.galleri.com/schedule)

21. How do I return the Galleri collection kit after my blood draw?

The trained technician who draws your blood will pack and ship your sample back to the GRAIL laboratory for processing. Everything needed to complete the blood and return the sample is within the Galleri kit.

If you or your blood draw technician has questions, please call Customer Service: [\(833\) 694-2553](tel:8336942553)

22. Do I need to fast before the blood draw?

No, fasting is not required for the Galleri test.

23. How much blood is drawn for the Galleri test?

Approximately 1.5 tablespoons (or about 20 mL) of blood in two tubes from a vein in your arm.

24. How do I cancel my test order if I no longer want to receive my results?

If you no longer wish to receive your Galleri results, contact GRAIL Customer Service by calling [\(833\) 694-2553](tel:8336942553).

25. When will Galleri test results be available?

Your sample will arrive at the GRAIL lab one to two days after your blood draw. Test results will be available about two weeks after your sample is received at the GRAIL lab.

If you participated in an onsite blood draw sponsored by your employer results may take as long as three weeks.

26. How do I request my Galleri test result report?

Your test results can be requested by contacting GRAIL Customer Service by calling [\(833\) 694-2553](tel:8336942553).

Understanding Your Test Results

27. What does it mean if I receive a “Cancer Signal Detected” result?

The Galleri test detected DNA methylation patterns that are often associated with cancer in your blood sample. About 1 out of every 100 tests has a Cancer Signal Detected result.⁹

This result will also include a prediction of the tissue type or organ associated with the cancer signal, called a Cancer Signal Origin. This helps your doctor determine the next steps for diagnosis.

Results should be interpreted by a healthcare provider. This test result is not a cancer diagnosis and requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider to confirm cancer. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps. Please note that false positive results do occur.

28. What does it mean if I receive a “No Cancer Signal Detected” result?

The Galleri test looked for a cancer signal in your blood sample and did not find one. This result does not completely rule out the possibility of cancer. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. Continue with routine cancer screenings your healthcare provider recommends.

A Galleri result of No Cancer Signal Detected does not rule out cancer.

29. Why does the Galleri test need to be used in addition to other single-cancer screening tests such as colonoscopy or mammography?

The Galleri test is intended to be used in addition to, and not replace, other cancer screening tests your healthcare provider recommends. Single-cancer screening tests are recommended because they have been proven to save lives by detecting cancer early.

Using Galleri in addition to recommended single-cancer screenings can increase your chances of detecting cancer early, to allow for earlier treatment.

Galleri does not detect a signal for all cancers and not all cancers can be detected in the blood.

30. Why are additional diagnostic tests needed with a “Cancer Signal Detected” result?

A Cancer Signal Detected test result is not a cancer diagnosis. A Cancer Signal Detected result requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider. GRAIL also offers patients and providers additional support and resources if needed to help guide next steps.

31. Can you share my Galleri test result with one of my healthcare providers?

All results are automatically shared with the provider who ordered the test. When requesting the test, you may provide the information for your primary care provider. If you would like us to fax your results to an additional healthcare provider, please contact Customer Service by calling (833) 694-2553 to receive instructions on how to complete a results release form.

32. I have medical coverage through Kaiser, what are my next steps if I receive a “Cancer Signal Detected” result?

A Cancer Signal Detected test result is not a cancer diagnosis. A Cancer Signal Detected result requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider. If you have a Cancer Signal Detected result the ordering provider will call you to discuss the result report and to provide guidance on next steps. The Galleri Patient Advocate team will also contact you to offer any support or assistance needed. If you do not already have a provider, the Galleri Patient Advocate team can assist with finding a provider in your Kaiser network.

If you have any questions, please contact Customer Service by calling (833) 694-2553.

33. I have medical coverage through UHC, what are my next steps if I receive a “Cancer Signal Detected” result?

A Cancer Signal Detected test result is not a cancer diagnosis. A Cancer Signal Detected result requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider. If you have a Cancer Signal Detected result the ordering provider will call you to discuss the result report and to provide guidance on next steps. The Galleri Patient Advocate team will also contact you to offer any support or assistance needed. If you do not already have a provider, the Galleri Patient Advocate team can assist with finding a provider in your UHC network.

If you have any questions, please contact Customer Service by calling (833) 694-2553.

34. I have medical coverage through the self-funded medical plan, what are my next steps if I receive a “Cancer Signal Detected” result?

A Cancer Signal Detected test result is not a cancer diagnosis. A Cancer Signal Detected result requires follow-up diagnostic testing which may include lab work or imaging ordered by your healthcare provider. If you have a Cancer Signal Detected result the ordering provider will call you to discuss the result report and to provide guidance on next steps. The Galleri Patient Advocate team will also contact you to offer any support or

assistance needed. If you do not already have a provider, the Galleri Patient Advocate team can assist with finding a provider in your network.

If you have any questions, please contact Customer Service by calling (833) 694-2553.

1. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings. [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results
2. American Cancer Society Cancer Facts and Figures 2023. Available at: <https://www.cancer.org/content/...> GRAIL, Inc. Data on file GA-2021-0065
3. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. *Ann Oncol*. 2021 Sep;32(9):1167-77. doi: [10.1016/j.annonc.2021.05.806](https://doi.org/10.1016/j.annonc.2021.05.806)
4. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Regs, 2020 Nov Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released 2021 Apr, based on the 2020 Nov submission. [Risk Factor Data on file: American Cancer Society Cancer Prevention Studies II/III.]
5. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Ann Oncol*. 2020 Mar 30;31(6):745-59. doi: [10.1016/j.annonc.2020.02.011](https://doi.org/10.1016/j.annonc.2020.02.011)
6. Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. *Cancer Metastasis Rev*. 2016 Jul 8;35:347–76. doi: [10.1007/s10555-016-9629-x](https://doi.org/10.1007/s10555-016-9629-x)
7. American Cancer Society. Lifetime risk of developing or dying from cancer. [cited 2023 Oct 11]. <https://www.cancer.org/cancer/cancer-basics/lifetime-probability-of-developing-or-dying-from-cancer.html>
8. NIH, National Cancer Institute. Genetic testing for inherited cancer susceptibility syndromes. [cited 2023 Mar 3]. <https://www.cancer.gov/about-cancer/causesprevention/genetics/genetic-testing-fact-sheet>
9. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. *Lancet*. 2023;402:1251-1260. doi:[10.1016/S0140-6736\(23\)01700-2](https://doi.org/10.1016/S0140-6736(23)01700-2)